Zai Lab Believes its Engagement of KPMG LLP is Consistent with PCAOB Requirements and Complies with the HFCAA Read more about Zai Lab Believes its Engagement of KPMG LLP is Consistent with PCAOB Requirements and Complies with the HFCAA
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv) Read more about Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting Read more about Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting
Zai Lab’s Statement Regarding U.S./China Agreement Concerning PCAOB Inspection and Review of Auditors Read more about Zai Lab’s Statement Regarding U.S./China Agreement Concerning PCAOB Inspection and Review of Auditors
Zai Lab Announces Participation in September Investor Conferences Read more about Zai Lab Announces Participation in September Investor Conferences
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia Read more about Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
Zai Lab to Announce Second Quarter 2022 Financial Results on August 9, 2022 Read more about Zai Lab to Announce Second Quarter 2022 Financial Results on August 9, 2022
Zai Lab Announces Inclusion of its Ordinary Shares in Two Stock Connect Programs Read more about Zai Lab Announces Inclusion of its Ordinary Shares in Two Stock Connect Programs
Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis Read more about Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis